Drugs Made In America Acquisition Corp. Ordinary Shares
Price Action
Technical Summary
STAGE 2 UPTRENDDrugs Made In America Acquisition Corp. Ordinary Shares is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 51), indicating performance broadly in line with the market. Earnings growth of 1500% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $10.55 | +0.44% | ABOVE |
| 50 SMA | $10.52 | +0.81% | ABOVE |
| 100 SMA | $10.46 | +1.32% | ABOVE |
| 150 SMA | $10.41 | +1.78% | ABOVE |
| 200 SMA | $10.38 | +2.14% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is DMAA in an uptrend right now?
DMAA has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, DMAA is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is DMAA overbought or oversold?
DMAA's RSI (14) is 71. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is DMAA outperforming the market?
DMAA has a Relative Strength (RS) Rating of 51 out of 99. DMAA is performing about average compared to the market.
Where is DMAA in its 52-week range?
DMAA is trading at $10.60, which is 100% of its 52-week high ($10.60) and 100% above its 52-week low ($10.09).
How volatile is DMAA?
DMAA has a Beta of 0.00 and 52-week volatility of 2%. It moves roughly in line with the overall market.